XLO - Xilio Therapeutics GAAP EPS of -$0.82 misses by $0.08 March, 02 2023 04:45 PM Xilio Therapeutics Inc. Xilio Therapeutics press release ( NASDAQ: XLO ): Q4 GAAP EPS of -$0.82 misses by $0.08 . Ended 2022 with $120.4 million in cash and cash equivalents; continue to anticipate cash runway into the second quarter of 2024 For further details see: Xilio Therapeutics GAAP EPS of -$0.82 misses by $0.08